PROJECT SUMMARY/ABSTRACT
We seek to discover novel biomarkers and drug targets for frontotemporal dementia (FTD) and related
disorders. FTD is a fatal neurodegenerative disorder that demonstrates substantial clinical, genetic, and
pathological overlap with amyotrophic lateral sclerosis (ALS). Although both diseases can display TAR DNA-
binding protein 43 (TDP-43) pathology, much remains unknown about the underlying mechanisms. It has been
suggested that RNA processing pathways play a vital role, which is exemplified by the description of mutations
in genes encoding RNA-binding proteins and the abundance of splicing defects in TDP-43 proteinopathies.
Given the fact that long-read sequencing techniques have a higher accuracy in splice junctions, a better
recovery of large transcripts, and detect more alternative splicing events than traditional sequencing methods
that rely on short reads, we will produce full-length long-read transcriptomic data. We will examine a well-
characterized pathological cohort of patients belonging to the FTD-ALS spectrum for whom frontal cortex and
cerebellar tissue are available. Additionally, we will create single-nuclei long-read sequencing data, enabling us
to determine in which cell type specific transcript variants are detected. This innovative approach will allow us
to capture transcriptomic diversity, aiding the identification of novel, disease-specific, and/or disease-relevant
transcript variants (Aim 1). We will compare the RNA signature observed in the brain to that seen in a large
collection of clinical blood specimens. Moreover, we will assess differences between presymptomatic and
symptomatic individuals and evaluate changes over time. These studies give us the ability to reveal interesting
biomarker candidates, which will be validated in our extensive biospecimen collection (Aim 2). To elucidate the
mechanisms underpinning these diseases, we will also perform in-depth mechanistic studies using various cell
culture models, in vivo systems, and post-mortem tissues from patients along the FTD-ALS spectrum (Aim 3).
Our original strategy, thorough characterization, and precious sample collection, will accelerate the
discovery of pathological mechanisms, druggable targets and translatable biomarkers, which are highly
valuable in preparation of future clinical trials for FTD and related disorders.
